Clinical Trials

Clinical Trial Detail

Search Clinical Trials

Return to search results.

A Phase 1 Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Complete title: A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin’s Lymphoma (NHL)

Research Study Number       20110654
    
Principal Investigator       Ajay Gopal, MD
    
Phase       I

Look up trial at NIH

Research Study Description

Phase 1 dose escalation study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb). Safety and dose-finding study of PF-05082566 single agent in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).

Eligibility Criteria (must meet the following to participate in this study)

Ages Eligible for Study: 18 Years and older

Genders Eligible for Study: Both

- Adequate bone marrow, renal, liver and cardiac function

- Exclusion Criteria:

- Autoimmune disorders, CNS malignancies

Other eligibility criteria may apply.



Research Study Number       20110654
    
Contact       Seattle Cancer Care Alliance Intake Office
    
Telephone       800-804-8824 / 206-288-1024
    
    

Keywords
Hematologic Malignancies; Lymphoma; Non-Hodgkin's Lymphoma (NHL)

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.